Securities Code: 003020
Securities Abbreviation: Lifu Pharmaceutical
Announcement No.: 2026-027
Hefei Lifu Pharmaceutical Co., Ltd.
Announcement on Company Products Selected for National Centralized Drug Procurement
The Company and all members of the Board of Directors guarantee the content of this information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Hefei Lifu Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Lifu Pharmaceutical") was recently notified that it has been selected for the 12th batch of national centralized drug procurement organized by the National Joint Procurement Office for Drugs (hereinafter referred to as the "Joint Procurement Office"). For specific details, please refer to the "Announcement on Company Products Selected for National Centralized Drug Procurement" (Announcement No.: 2026-026) disclosed by the Company on August 3, 2026, in the China Securities Journal, Shanghai Securities News, and the Juchao Information Network (http://www.cninfo.com.cn).
The Joint Procurement Office issued the "Notice on the Announcement of the Selection Results for the 12th Batch of National Centralized Drug Procurement" (GY-YD2026-1) on August 6, 2026. The relevant progress is hereby announced as follows:
I. Basic Information of Selected Products